The Current: Discovering Chemistry's Zeitgeist

Vision, Persistence, and Legacy – A Cinematic Conversation with a mentor- Dr. Robert Langer, MIT Institute Professor and Co-Founder of Moderna---Step into a cinematic and motivational experience with one of the most prolific minds in science and innovation — Dr. Robert S. Langer, Sc.D. In this special episode, we feature powerful reflections from Dr. Langer on vision, perseverance, mentorship, innovation, and legacy. His voice, uncut and authentic, is paired with dynamic open source music to inspire the next generation of dreamers and doers.This episode includes Spanish translations of key moments to make the wisdom accessible to a broader audience across the globe.From foundational discoveries in drug delivery and tissue engineering to cultivating the next wave of scientific leaders, this audio journey brings depth and cinematic inspiration to Dr. Langer’s words.🎶 Music Note: This episode features open source instrumental tracks carefully arranged to elevate the listening experience while respecting the clarity of Dr. Langer’s message.Disclaimer:The views of this podcast reflect those of my guests and I, and do not constitute medical or professional advice or consultation. Please see a state certified and board-certified health professional for medical and professional advice. Again, we disclaim any loss in any way, and this podcast does not in any way represent a company endorsement and medical recommendation.

The Riemann Key: Unlocking Modern Nobel Discoveries of the Past with a 19th-Century Thesis--Please note the views of this podcast represent those of my guest and I, and AI may have been used in the production of the episode. Please see a board-certified medical professional, that is state licensed for medical or professional advice. We disclaim any loss in any way.

"From BMES to the States: Excellence, Athletics, and Building Bridges Across Cultures"- A Conversation with Antonio Smith, A Longstanding Highschool Friend and Quality Control Leader---Episode Description:Join me for a cool conversation with one of my closest friends, Antonio Smith, as we dive deep into a journey that spans two countries, multiple sports, and the pursuit of excellence that started at Bishop Michael Eldon School in FreeportAntonio made the bold decision to leave one of the Bahamas' top schools in his senior year to pursue opportunities in Tallahassee, Florida. From competing in three sports at James S. Richards High School to building a successful career as a Quality Control Team Lead at KUS, his story embodies the resilience and work ethic that elite Bahamian education instills.We explore the cultural bridges between the Bahamas and the United States, the challenges of maintaining community connections while building a new life abroad, and the entrepreneurial spirit that led him to co-found a shopping and shipping company serving the Bahamian diaspora. This conversation touches on athletics, education, career development, cultural identity, and the ongoing connection to home that shapes the immigrant experience.Whether you're interested in Caribbean education systems, the student-athlete experience, quality control leadership, or the dynamics of diaspora communities, this episode offers authentic insights from someone who has successfully navigated multiple worlds while maintaining his roots.Topics Covered:Elite Bahamian education and its impact on character developmentStudent-athlete transitions between Caribbean and American systemsCareer progression from physical education studies to quality control leadershipEntrepreneurship within diaspora communitiesMaintaining cultural identity while adapting to new environmentsThe realities of building a life between two countriesDisclaimer:The views and experiences shared in this episode are those of the guest and host based on their personal journeys. While we discuss educational institutions, athletic programs, and cultural comparisons, these perspectives reflect individual experiences and should not be considered representative of all students, athletes, or community members from these backgrounds. Career and life decisions discussed are personal choices that may not be suitable for everyone. Listeners considering similar educational or geographic transitions should conduct their own research and seek appropriate guidance for their specific circumstances.The views expressed do not constitute medical or professional advice. Please see a board certified and state licensed health professional for medical and professional advice. We disclaim any loss in any way.Music citation: Music by Andrii Poradovskyi from Pixabay

From Lab Bench to Bedside: Cardiolipin Science Saves Lives- The Significant Connection between D.J. Ferguson's Master's Thesis and Forzinity's Recent Approval----On September 19, 2025, the FDA granted accelerated approval to FORZINITY™ (elamipretide), a groundbreaking new drug for Barth syndrome—an ultra-rare genetic disorder affecting only about 150 people in the United States. On the surface, it's a monumental victory for a small but desperate community. But what if this victory is also a critical clue, a key that could unlock a new frontier in the fight against some of the world's most widespread neurological diseases?This approval marks the first-ever therapy specifically targeting mitochondria, the powerhouses of our cells. The implications are staggering, potentially paving the way for new approaches to treating conditions like Alzheimer's and Parkinson's, where mitochondrial dysfunction is a known culprit.Join us as we unravel this historic first, exploring the intricate science and the decade-long journey of perseverance that led to this moment.In this episode, we explore:The World of Barth Syndrome: We define this devastating and ultra-rare genetic disease, understanding its profound impact on patients and the cellular machinery it disrupts.The Unsung Hero of Our Cells: A deep dive into the science of mitochondria and a crucial molecule you’ve likely never heard of—cardiolipin. Learn why this unique phospholipid is the linchpin of cellular energy and structural integrity.A Targeted Therapy: Discover how FORZINITY™ (elamipretide) works by directly interacting with and stabilizing cardiolipin, restoring function at the very source of the problem.The Road to Approval: We chart the high-stakes, dramatic journey of Stealth BioTherapeutics, from a major FDA rejection to a strategic pivot that secured a historic accelerated approval.The Broader Horizon: We connect the dots from Barth syndrome to neurodegeneration, exploring the mounting evidence that links cardiolipin dysfunction to the pathology of Alzheimer's and Parkinson's disease, and what this breakthrough means for the future of medicine.Disclaimer:The views of this podcast reflect those of my guests and I, and do not constitute medical or professional advice or consultation. Please see a state certified and board certified health professional for medical and professional advice. Again, we disclaim any loss in any way, and this podcast does not in any way represent a company endorsement and medical recommendation.Link: Understanding Cardiolipin's Function in Neurodegenerative Diseases- A Flashback | Research Communities by Springer Nature

The Path to KOLs--Ukranian Episode: Шлях до KOL: Наука, Лідерство та Сила Малих Кроків (The Path to KOL: Science, Leadership, and the Power of Small Steps)--До кожного, хто переживає складний період: пам’ятайте, що тіні є доказом існування світла. Коли шлях уперед незрозумілий, а тягар світу здається надто важким, тримайтеся за тиху силу, яка живе всередині вас.Як нагадував доктор Мартін Лютер Кінг, молодший: «Віра — це зробити перший крок, навіть коли ви не бачите всієї сходової клітки». Ваша подорож не полягає в тому, щоб бачити кінець від самого початку, а в тому, щоб мужньо зробити наступний крок. У хвилини випробувань ми часто знаходимо найбільші можливості.Ласкаво просимо до “Шляху до KOL” — студентського подкасту, що надихає студентів клінічної фармації, майбутніх резидентів та молодих клініцистів. У кожному епізоді беруть участь світові лідери думок — канцлер Ґері Мей; доктор Роберт Ленґер; Ґреґ Цукерман (The Wall Street Journal); Кайл Вумн (Forbes 30 Under 30) — які діляться своїми поглядами на проривні дослідження, лідерство, інновації та кар’єри у фармації, орієнтовані на цінності й мету.Нехай виклики, з якими ви стикаєтесь, зміцнюють вашу рішучість. Як писав святий Августин: «У надії є дві прекрасні дочки: їхні імена — Гнів і Відвага. Гнів на те, що є, і Відвага, щоб зробити так, аби все не залишалось таким самим». Використовуйте цю відвагу не в одному великому жесті, а в малих, послідовних діях, які ви робите щодня. Мати Тереза навчала простої, але глибокої істини: «Ми не можемо робити великих справ, лише маленькі справи з великою любов’ю».Відмова від відповідальності: цей контент не є медичною порадою чи рекомендаціями. Звертайтеся за порадами до сертифікованих медичних фахівців на рівні ради, штату чи місцевих органів. Ми відмовляємося від будь-якої відповідальності за будь-які втрати.----English:To anyone navigating a difficult season, remember that the shadows are proof of the light. When the path ahead is unclear and the weight of the world feels heavy, hold on to the quiet strength that resides within you.As Dr. Martin Luther King, Jr. reminded us, "Faith is taking the first step even when you don't see the whole staircase." Your journey is not about seeing the end from the beginning, but about bravely taking that next step. In moments of trial, we often find our greatest opportunities. Welcome to The Path to KOL, the student-led podcast empowering clinical pharmacy students, residency aspirants & rising clinicians. Each episode features global thought leaders—Chancellor Gary May; Dr Robert Langer; Greg Zuckerman (The Wall Street Journal); Kyle Woumn (Forbes 30 Under 30)—sharing insights on breakthrough research, leadership, innovation & purpose-driven pharmacy careers.Let the challenges you face fuel your resolve. As St. Augustine wrote, "Hope has two beautiful daughters; their names are Anger and Courage. Anger at the way things are, and Courage to see that they do not remain as they are." Use that courage not in one grand gesture, but in the small, consistent actions you take every single day. Mother Teresa taught a simple yet profound truth: "We can do no great things, only small things with great love."Disclaimer: This content is not medical advice or suggestions. Consult board-, state-, and locally certified health professionals for medical advice. We disclaim any liability for any loss.

In this episode, join us for an inspiring conversation again with Dr. Robert Langer, Sc.D. (MIT), as he shares invaluable advice on navigating a successful scientific career and offers a glimpse into the future of nanoscience. In this episode, we explore:Professional Development:Dr. Langer discusses how early-career scientists can build strong, cross-disciplinary partnerships and the key habits and mindsets that helped him transition from bench research to world-changing innovation. He also reflects on how his mentorship approach has evolved over decades, providing guidance to those pursuing leadership roles at the nexus of academia and industry.---Questions:Professional Development:Throughout your career, you've emphasized interdisciplinary collaboration. How can emerging scientists strategically cultivate effective, multidisciplinary partnerships early in their professional journeys?Reflecting on your own professional trajectory, what habits or mindsets do you believe were most crucial in transitioning successfully from scientific inquiry to impactful innovation?How have your mentorship strategies evolved over the years, especially when guiding individuals pursuing leadership roles at the intersection of academia and industry?Considering recent advancements, what novel areas within nanoscience do you find most promising or surprising, particularly those relevant to medical applications?How do you foresee the integration of nanoscience with other disciplines (like artificial intelligence or bioinformatics) reshaping pharmaceutical and biomedical research over the next decade?Could you highlight a recent breakthrough or approach in your lab related to nanoscience that significantly changed your thinking about future therapeutic possibilities?When you developed curricula for math and science education, what core principles guided your approach to ensuring both depth of content and accessibility to diverse learners?How did you balance rigorous scientific accuracy with the practical engagement of students who might not initially be inclined towards STEM subjects?Reflecting on the implementation phase, what strategies or frameworks were most effective in training educators to deliver complex scientific concepts confidently?In your experience, what differentiates a merely effective textbook from one that genuinely inspires students and significantly advances their understanding of scientific concepts?Given your extensive experience, what critical components or features should I emphasize or enhance in my upcoming chemistry  textbooks to better support active learning and critical thinking?Based on your observations, what common pitfalls should be avoided when structuring textbooks intended for advanced high school or undergraduate science courses?Considering current global challenges, how can aspiring scientists and educators ensure their contributions remain impactful, relevant, and grounded?Finally, could you share a recent experience or insight that profoundly influenced your views on education, mentorship, or scientific innovation?----Note: The views of this podcast reflect those of my guest(s) and I.

Remixed- Path to KOLs: The New Chemist Podcast’s Global Journey in Science, Pharma, and Education: Interview with Mohan Uttarwar, CEO & Co-Founder of 1Cell.Ai---In this episode we provide and educational episode remix made with software assistance ( for educational purposes only) , we sit down with Mohan Uttarwar, CEO & Co-Founder of 1Cell.Ai, to explore how AI-driven single-cell analytics are revolutionizing precision oncology. Discover how the OncoIncytes platform merges ctDNA, live CTCs, single-cell RNA and proteomics for a real-time, multimodal tumor profile—and learn how these insights are sharpening patient selection, accelerating ADC trials, and delivering earlier, more accurate measures of therapeutic response. Mohan also shares his playbook for building a capital-efficient biotech across Silicon Valley and India, the emerging trends set to reshape drug development, and practical advice for chemists, data scientists, and founders looking to break into the field. Tune in this August for a deep dive into the future of cancer research and drug discovery.--Please note: The views of this podcast represent those of my guest(s) and I, and do not constitute professional or medical advice or consultation. Please see a medical professional or healthcare professional for advice, suggestions and consultations. We disclaim any loss in any way.Music citation: Open source

The Path to KOLs: Nobel Lecture Compendium ( 100+) with AI-Powered OverviewsIn this episode, we compile over 100+ Nobel Lectures and key lectures and use AI LLMs to produce video overviews of those lectures.Please note: The views of this podcast represent those ofmy guest and I, and do not constitute medical, professional or financial advice or consultation. Please refer to the state and board-certified professionals. We disclaim any loss in any way.

Episode Description: In this episode, we sit down with Sam Libby, President and Managing Director at TCB Capital Advisors, whose career has been dedicated to transforming healthcare through strategic investments and partnerships. With more than 30 completed transactions —spanning mergers and acquisitions, capital raises, and innovative deal structures—Sam has become a trusted advisor at the intersection of finance, science, and patient care. Our conversation dives deep into his origin story—fromRutgers to leading one of the most dynamic advisory firms in healthcare—and explores how his investment philosophy balances patient-centered missions with the financial discipline demanded by markets. Sam shares case studiesfrom groundbreaking ventures like Clairity, the first FDA-cleared AI breast cancer risk platform, and Altoida, a pioneer in early cognitive assessment technology, offering valuable lessons for founders and investors alike.We also discuss the critical role of strategic partnerships, the evolving dynamics between founders and investors, and the exciting frontiers shaping the future of healthcare—from oncology and neurodegeneration to women’s health and digital innovation. Sam highlights how AI and data are reshaping deal-making, due diligence, and commercialization pathways. Finally, Sam offers practical advice for aspiring thought leaders and entrepreneurs on refining their pitch, stepping into leadership beyond the lab, and positioning themselves for long-term impact in arapidly evolving industry.Whether you’re a scientist, entrepreneur, investor, orfuture healthcare leader, this episode provides insightful perspectives on the business of innovation, the art of deal-making, and the mission to improvepatient outcomes.Music citation: open source classical musicPlease note: The views of this podcast represent those of my guest and I, and do not constitute medical, professional or financial advice or consultation. Please refer to the state and board-certified professionals. We disclaim any loss in any way.

🎙️ Episode DescriptionIn this episode, we sit down with Sam Libby,President and Managing Director at TCB Capital Advisors, whose career has been dedicated to transforming healthcare through strategic investments andpartnerships. With more than 30 completed transactions —spanning mergers and acquisitions, capital raises, and innovative deal structures—Sam has become a trusted advisor at the intersection of finance, science, and patient care. Our conversation dives deep into his origin story—from Rutgers to leading one of the most dynamic advisory firms in healthcare—and explores how his investment philosophy balances patient-centered missions withthe financial discipline demanded by markets. Sam shares case studies from groundbreaking ventures like Clairity, the first FDA-cleared AI breast cancer risk platform, and Altoida, a pioneer in early cognitive assessment technology, offering valuable lessons for founders and investors alike.We also discuss the critical role of strategicpartnerships, the evolving dynamics between founders and investors, and the exciting frontiers shaping the future of healthcare—from oncology and neurodegeneration to women’s health and digital innovation. Sam highlights how AI and data are reshaping deal-making, due diligence, and commercialization pathways.Finally, Sam offers practical advice for aspiringthought leaders and entrepreneurs on refining their pitch, stepping into leadership beyond the lab, and positioning themselves for long-term impact in a rapidly evolving industry. Whether you’re a scientist, entrepreneur, investor, or future healthcare leader, this episode provides insightful perspectives on the business of innovation, the art of deal-making, and the mission to improvepatient outcomes.

A Highly Ranked Episode for the Overall Group: TNCPG Remix-Fireside Chat Remix - Interview with Simar Bajaj (Harvard University) ( Re-aired)----In this fireside chat remixed episode and podcast interview with Simar, a Marshall Scholar and graduate of Harvard University, we discuss Simar's achievements in science communication, his perseverance, and the hard work required to produce good work, science communication, and good journalism. Furthermore, Simar provides insights as he is a developing and achieving young leader in the science and journalism arenas. Definitely an episode worth listening to!Here are the links to his website and LinkedIn Page:1. Simar's website: https://www.simarbajaj.com/2. Simar's LinkedIn: https://www.linkedin.com/in/simar-bajaj/----Note: The views of this podcast represent those of my guest(s) and I.Note: Purpose of these episodes- not at all, for advice or medical suggestions. These are aimed to provide support for peer pharmacists in training in educational andintellectually stimulating ways. Again, these are not at all for medical advice, or for medical suggestions. Please see your local state and board-certified physician, PA or NP, and pharmacist for medical advice andsuggestions.---Recorded in 2023

In this episode of The New Chemist’s Podcasting Group’s — The Path to KOLs, host David Ferguson sits down with Christine Hollis, Chief Talent & Diversity Officer at Marshall Gerstein. Christine has dedicated her career to guiding scientists and engineers into impactful roles within intellectual property law, bridging the worlds of innovation and legal protection.She shares insights on:Pathways for STEM talent to enter IP law as patent agents or technical specialists.The skills scientists bring to legal environments and innovation ecosystems.Strategies for diversity, equity, and inclusion in science-driven law.The future of STEM-law collaboration in an era of AI, biotech, and medtech.Whether you’re a student, scientist, or innovator, Christine’s vision will broaden your perspective on how STEM expertise can shape industries beyond the lab.Disclaimer: These episodes do not constitute medical or professional advice. These are only for intellectual engagement. Please see your local and board-certified health professional for medical advice, consultation, and suggestions.Music by Viacheslav Starostin from Pixabay

The New Chemist’s Podcasting Group — The Path to KOLs: Accelerating First-in-Human in LATAM — Julio G. Martinez-Clark, CEO, bioaccess® w/ Chadwin Hanna, MD-PhD Student (UF) and David Ferguson (Host)---On The Path to KOLs from The New Chemist’s Podcasting Group, hosts David Ferguson and Chadwin Hanna explore how Latin America is becoming a strategic engine for high-quality, cost-effective clinical research.Julio G. Martinez-Clark—Ambassador of IAOCR/GCSA Americas and CEO of bioaccess®—breaks down how aligning to global competence standards and smarter site activation can compress timelines for First-in-Human and Early Feasibility Studies without compromising quality. He shares lessons from pioneering trials, practical blueprints for building city-level clinical hubs, and pragmatic guidance for innovators entering LATAM markets. The conversation also touches on sustaining regional infrastructure, cross-border collaboration, and the mindset behind his long-running Global Trial Accelerators™ series.Guest: Julio G. Martinez-Clark, CEO, bioaccess®Hosts: David Ferguson, BS, MS, Pharm.D. Candidate; Chadwin Hanna, MD Candidate & PhD StudentPlease note: The views of this podcast reflect those of my guest(s) and I, and do not constitute medical advice, consultation and suggestions. Please see a board certified and state licensed medical professional.

The New Chemist’s Podcasting Group: The Path to KOLs — Interview with Dr. Michael A. Morris, MD, MS, DABR, DABNM, DCI — Co-Founder, United Theranostics---🎙️ In this episode of The Path to KOLs, Dr. Michael A. Morris, MD, MS, DABR, DABNM, DCI—co-founder of United Theranostics—explains how his team is moving Pluvicto from single mega-centers into safe, consistent community clinics. We dig into the toughest regulatory and logistical hurdles, the playbook for dosing accuracy, imaging quality, and safety, and how clinics are designed for a compassionate, family-centered patient journey with real-world feedback loops.Dr. Morris also shares how United Theranostics trains local technologists, pharmacists, and nurses, mentors future KOLs, and maps a path to coverage across all 50 states. Looking ahead, we discuss what’s beyond Pluvicto—including actinium-225 PSMA approaches—and how telehealth, remote monitoring, and AI are improving patient selection, follow-up, and outcomes.About the guest: Dr. Morris is a physician-scientist in nuclear medicine, diagnostic radiology, and clinical informatics; Medical Director in Glen Burnie, MD; adjunct faculty at the University of Miami and University of Maryland; and a principal investigator on multiple FDA clinical trials in prostate cancer and neuroendocrine tumors.Subscribe for actionable insights at the intersection of innovation, operations, and patient-centered care.Music by Dmitrii Kolesnikov from PixabayPlease note: The views of this podcast reflect those of my guest(s) and I, and do not constitute in any way medical advice or consultation. Please see a board and state certified medical professional for advice, consultation and suggestions.

The Making of KOLs: The New Chemist Podcast’s Global Journey in Science, Pharma, and Education: Interview with Mohan Uttarwar, CEO & Co-Founder of 1Cell.Ai---In this episode , we sit down with Mohan Uttarwar, CEO & Co-Founder of 1Cell.Ai, to explore how AI-driven single-cell analytics are revolutionizing precision oncology. Discover how the OncoIncytes platform merges ctDNA, live CTCs, single-cell RNA and proteomics for a real-time, multimodal tumor profile—and learn how these insights are sharpening patient selection, accelerating ADC trials, and delivering earlier, more accurate measures of therapeutic response. Mohan also shares his playbook for building a capital-efficient biotech across Silicon Valley and India, the emerging trends set to reshape drug development, and practical advice for chemists, data scientists, and founders looking to break into the field. Tune in this August for a deep dive into the future of cancer research and drug discovery.--Please note: The views of this podcast represent those of my guest(s) and I.Music citation: Open source

In our most ambitious double‑header yet, host David J. Ferguson welcomes two visionary Key Opinion Leaders:Dr. Shane Campbell‑Staton – Princeton evolutionary biologist and two‑time Emmy‑nominated host of PBS’s Human Footprint. He reveals how urban heat, extreme weather, and radiation zones forge rapid genetic shifts in lizards, wolves, elephants, and more.Chancellor Gary May – Engineer, STEM‑equity champion, and Chancellor of UC Davis (former Georgia Tech Dean who co‑launched the groundbreaking Online MS in Computer Science). He shares strategies for scaling inclusive STEM education, forging academia‑industry bridges, and cultivating the next wave of scientific innovators.What you’ll hear:Evolution at Warp Speed – Dr. Campbell‑Staton’s field‑to‑genome toolkit for tracking adaptation in real time.Science‑as‑Cinema – Turning dense data into binge‑worthy PBS storytelling.Inclusive Excellence – Chancellor May on building diverse talent pipelines and leveraging tech to democratize advanced degrees.Leadership Playbook – Advice on mentorship, funding partnerships, and navigating academia’s future.Forward Look – Big questions on human‑driven evolution and the university of tomorrow.Listen now on Apple Podcasts, Spotify, or your favorite app.---Background Music citation:  Mykola Odnoroh from Pixabay---Note: The views of this podcast represent those of my guests and I.

In this episode of The New Chemist’s Podcast, we’re thrilled to welcome the iconic Jason Mraz, a Grammy Award-winning singer-songwriter, known for timeless hits like "I’m Yours" and "Lucky". 🎶But Jason is more than just a musician—he is a passionate environmental advocate, using his platform to raise awareness about sustainability, regenerative agriculture, and soil health. 🌱 Joining him is Mr. Makespeace, an environmentalist dedicated to fostering change and protecting the planet. Together, they discuss their journeys in music and environmental activism, especially through their involvement in the Kiss the Ground movement.🎙️ Join David Ferguson as he, Jason, and Mr. Makespeace explore the intersection of creativity and advocacy, offering inspiring insights on how we can all contribute to a more sustainable future.Don’t miss this powerful conversation on music, mindfulness, and making a positive impact in the world !

In this interview we discuss Gabriel successful career thus far, and how to achieve those "5%" moments that complement to success, through networking and working hard. Definitely a good interview. Note: TNCC Podcasting division does not claim the rights to the music used in the podcast episode.

In this special episode of The New Chemist's Podcast, we explore the brilliance of Nobel Prize lectures in science, presented in both English and Hebrew. Join us as we highlight groundbreaking discoveries and honor the scientists who have shaped our understanding of the world—from Stockholm to the global stage.Please note the views of this podcast reflect those of my guest(s) and I. Also, these views do not constitute medical or professional advice. Please see the relevant board-certified and state licensed professionals.--בפרק מיוחד זה של הפודקאסט של הכימאי החדש, אנו בוחנים את הזוהר של הרצאות פרס נובל במדע, המוצגות באנגלית ובעברית. הצטרפו אלינו כשאנו מדגישים תגליות פורצות דרך ומכבדים את המדענים שעיצבו את הבנתנו את העולם - משטוקהולם ועד לבמה העולמית.שימו לב שהדעות של הפודקאסט הזה משקפות את אלה של האורחים שלי ושלי. כמו כן, דעות אלה אינן מהוות ייעוץ רפואי או מקצועי. אנא פנה לאנשי המקצוע הרלוונטיים המוסמכים והמורשים על ידי המדינה.

Description:In this special bilingual episode, we explore the past Nobel Prizes in Chemistry, Medicine, and Economics. From groundbreaking mRNA research to advancements in quantum dots and behavioral economics, we unpack the science—and the stories—behind the world's most prestigious awards.本期特别节目，我们以中英双语带大家了解2024年诺贝尔奖中的三大重点领域：化学奖、医学奖与经济学奖。节目将介绍mRNA技术的医学突破、量子点的化学奇迹，以及行为经济学的新发展，一起探索这些改变世界的研究成果！Tune in to:Learn what each prize was awarded forHear insights from both scientific and global perspectivesPractice your Chinese and English listening skills in a natural, engaging context欢迎科学爱好者、语言学习者以及对诺贝尔奖好奇的你一同收听！🎧 Available now on all major platforms.🎙️ 请在各大平台搜索收听！--Some of the content produced involved the use of AI.